# Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

> **NCT02931539** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 352 (actual)

## Conditions studied

- Cytomegalovirus (CMV)

## Interventions

- **DRUG:** Maribavir
- **DRUG:** Ganciclovir
- **DRUG:** Valganciclovir
- **DRUG:** Foscarnet
- **DRUG:** Cidofovir

## Key facts

- **NCT ID:** NCT02931539
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2021-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02931539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02931539, "Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT02931539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*